These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23537065)

  • 1. X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?
    Topiol S
    Expert Opin Drug Discov; 2013 Jun; 8(6):607-20. PubMed ID: 23537065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray structure breakthroughs in the GPCR transmembrane region.
    Topiol S; Sabio M
    Biochem Pharmacol; 2009 Jul; 78(1):11-20. PubMed ID: 19447219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in G protein-coupled receptor purification yield light stable rhodopsin crystals.
    Salom D; Le Trong I; Pohl E; Ballesteros JA; Stenkamp RE; Palczewski K; Lodowski DT
    J Struct Biol; 2006 Dec; 156(3):497-504. PubMed ID: 16837211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
    Wang CI; Lewis RJ
    Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structures of class B G protein-coupled receptors: prospects for drug discovery.
    Hausch F
    Angew Chem Int Ed Engl; 2013 Dec; 52(49):12783-5. PubMed ID: 24127232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors.
    Valant C; Robert Lane J; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2012; 52():153-78. PubMed ID: 21910627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development.
    Müller CE; Schiedel AC; Baqi Y
    Pharmacol Ther; 2012 Sep; 135(3):292-315. PubMed ID: 22728155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists.
    Hagiwara Y; Ohno K; Kamohara M; Takasaki J; Watanabe T; Fukunishi Y; Nakamura H; Orita M
    Expert Opin Drug Discov; 2013 Aug; 8(8):951-64. PubMed ID: 23682717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPCR structures in drug design, emerging opportunities with new structures.
    Tautermann CS
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4073-9. PubMed ID: 25086683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are GPCRs still a source of new targets?
    Garland SL
    J Biomol Screen; 2013 Oct; 18(9):947-66. PubMed ID: 23945874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of GPCR structures in drug design.
    Congreve M; Langmead C; Marshall FH
    Adv Pharmacol; 2011; 62():1-36. PubMed ID: 21907905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
    Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
    Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody fragments for stabilization and crystallization of G protein-coupled receptors and their signaling complexes.
    Shukla AK; Gupta C; Srivastava A; Jaiman D
    Methods Enzymol; 2015; 557():247-58. PubMed ID: 25950968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPCR crystal structures: Medicinal chemistry in the pocket.
    Shonberg J; Kling RC; Gmeiner P; Löber S
    Bioorg Med Chem; 2015 Jul; 23(14):3880-906. PubMed ID: 25638496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous GPCR expression: a bottleneck to obtaining crystal structures.
    McCusker EC; Bane SE; O'Malley MA; Robinson AS
    Biotechnol Prog; 2007; 23(3):540-7. PubMed ID: 17397185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T; Menon S; Sakmar TP
    Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridging the gap: bitopic ligands of G-protein-coupled receptors.
    Lane JR; Sexton PM; Christopoulos A
    Trends Pharmacol Sci; 2013 Jan; 34(1):59-66. PubMed ID: 23177916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delaunay triangulation with partial least squares projection to latent structures: a model for G-protein coupled receptors classification and fast structure recognition.
    Wen Z; Li M; Li Y; Guo Y; Wang K
    Amino Acids; 2007 Feb; 32(2):277-83. PubMed ID: 16729188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs.
    Congreve M; Oswald C; Marshall FH
    Trends Pharmacol Sci; 2017 Sep; 38(9):837-847. PubMed ID: 28648526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology modeling of G-protein-coupled receptors with X-ray structures on the rise.
    Yarnitzky T; Levit A; Niv MY
    Curr Opin Drug Discov Devel; 2010 May; 13(3):317-25. PubMed ID: 20443165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.